Marketing
-
Orchard isn't for the picking, Biohaven's Allergan headache, and who's on Vascepa?
Amarin CEO John Thero had one question for investors eager to hear about his company's plans for its heart pill, while Orchard made a case for independence.
By Jacob Bell • Jan. 16, 2020 -
Lilly expands half-price insulin offerings
Like rivals Novo and Sanofi, Lilly has introduced lower cost insulin alternatives to head off criticism of list price increases it's taken on its branded versions.
By Ned Pagliarulo • Jan. 15, 2020 -
Nektar quickly drops opioid drug after FDA panel rejection
After a decade of research, the biotech said it will withdraw its application for oxycodegol and make no further investment in the drug.
By Kristin Jensen • Jan. 15, 2020 -
Amag CEO to step down as troubled pharma looks to sell 2 drugs
Emerging from an activist investor fight, Amag announced a restructuring plan and 2020 sales estimates that fell short of Wall Street expectations.
By Andrew Dunn • Jan. 09, 2020 -
GSK's plan to take over the HIV drug market hasn't worked out
An FDA rejection and modest sales for two marketed products are challenging GSK's argument that two-drug treatments are a better way to treat HIV.
By Jacob Bell • Jan. 06, 2020 -
Pfizer, AbbVie and Gilead among drugmakers boosting prices to start 2020
List prices rose on some of the top-selling medicines in the U.S., including Humira, Opdivo, Prevnar 13 and Biktarvy.
By Andrew Dunn • Jan. 02, 2020 -
Ultragenyx sells European royalty stake in rare disease drug for $320M
Royalty Pharma will add another stake to its expansive collection, while the California biotech gets an immediate injection of cash.
By Andrew Dunn • Dec. 18, 2019 -
SponsoredData alone can't make health improvements happen
Big tech could soon be playing the role of big brother in monitoring our health-related behaviors, with or without consumers' explicit buy-in.
By Pratap Khedkar • Dec. 03, 2019 -
Before 2019 closes, the FDA has 3 key approval decisions to make
The agency has been on an approval tear lately, and more may come as reviews for drugs from Amarin, Allergan and Intra-Cellular wrap up.
By Jacob Bell • Nov. 27, 2019 -
FDA's rapid review pace nets an early approval for Alnylam's second drug
Givosiran, which will be sold as Givlaari, is the second RNAi therapeutic cleared by the agency after Alnylam's Onpattro.
By Jonathan Gardner • Nov. 20, 2019 -
France clears way for wide use of Vertex's Orkambi
By agreeing to reimburse the drug beyond compassionate use, France opens up access to one of the largest cystic fibrosis populations outside the U.S.
By Jonathan Gardner • Nov. 20, 2019 -
Nascent digital therapeutics group lays out best practices, ethics
The two-year-old group is looking to differentiate higher-risk products that claim to treat disease from more general digital health and wellness apps.
By Susan Kelly • Nov. 13, 2019 -
Sage's new drug starts slow, as Wall Street waits for depression data
Few expected Sage's postpartum depression drug Zulresso to start fast. Sales of $1.5 million in its first full quarter on market confirmed those expectations.
By Ned Pagliarulo • Nov. 13, 2019 -
Walgreens reportedly mulling massive private equity buyout
The drugstore retailer is exploring a possible go-private deal, which would be the largest leveraged buyout in history, according to multiple media reports.
By Ben Unglesbee • Nov. 06, 2019 -
AstraZeneca's China ambitions grow with new R&D investments
Already a leader in China, the British pharma is doubling down with plans to open two new centers and launch a $1 billion biotech investment fund.
By Jonathan Gardner • Nov. 06, 2019 -
Third Neulasta biosimilar on its way as Sandoz wins long-delayed FDA approval
Novartis' drug will be third to market, but copycat drugs have already taken a chunk of the market away from Amgen's branded version.
By Jonathan Gardner • Nov. 05, 2019 -
SponsoredFive recent developments radically re-shaping new drug commercialization
Emerging companies and drug developers need a new game plan and new resources as their pipelines mature, often choosing to go solo where previous players partnered with others.
By Dominic Marasco, RPh • Nov. 01, 2019 -
Sanofi pays $315 million to settle Lemtrada go-slow claims
The administrator of a contingent value right tied to Sanofi's buyout of Genzyme argued the pharma slowed Lemtrada's progress to dodge billions in potential payouts.
By Jonathan Gardner • Oct. 31, 2019 -
FDA panel backs withdrawal of Amag drug to prevent preterm birth
An advisory committee narrowly recommended the FDA rescind approval for Makena, which showed no benefit in a confirmatory study.
By Ned Pagliarulo • Oct. 30, 2019 -
CMS proposes lifting restrictions on next-gen sequencing tests for cancer
The agency revised its proposed national coverage determination after receiving more than 80 comments, with plans to extend coverage of next generation sequencing tests to earlier-stage and hereditary cancers.
By Nick Paul Taylor • Oct. 30, 2019 -
Gilead CAR-T sales slow, renewing growth doubts
Yescarta, the cell therapy Gilead acquired in its $12 billion deal for Kite, appeared to hit a snag, with sales from July to September declining versus the second quarter.
By Ned Pagliarulo • Oct. 25, 2019 -
Vertex clears its biggest commercial hurdle: UK insurance coverage
After months of testy negotiations, Vertex and English health authorities have created a reimbursement plan for the company's cystic fibrosis drugs.
By Jacob Bell • Oct. 24, 2019 -
5 insights from a chat with Larry Merlo, CEO of CVS Health
Healthcare Dive talked to Merlo about competing with Amazon, the path to buying Aetna and new areas in which CVS could play a role.
By Rebecca Pifer • Oct. 23, 2019 -
SponsoredAssessing provider (and patient) motivation
Behavioral science provides a roadmap to understanding how HCPs make decisions and what drives prescribing behavior, but more importantly, it gives us strategies that we can apply to disrupt the status quo.
By Patty Zipfel, PhD, ISMPP, CMPP™ VP, Scientific Strategy MicroMass Communications, Inc. • Oct. 23, 2019 -
Novartis' Zolgensma starts strong as about 100 infants are treated with gene therapy
Sales totaled $160 million in the gene therapy's first full quarter of commercial availability, well above Wall Street's expectations.
By Andrew Dunn • Oct. 22, 2019
